Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.36 |
| ▸ | BRS3 | P32247 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948152 | 0.88 | ACHE (0.44) | TP53 | |
| SCHEMBL19616976 | 0.88 | ACHE (0.44) | TP53 | |
| SCHEMBL19948150 | 0.86 | SLC6A7 (0.37) | CHRM4GRM2 | |
| SCHEMBL30675362 | 0.86 | OPRD1 (0.42) | SMN1; SMN2MEN1KMT2ACHRM4 | |
| SCHEMBL28905734 | 0.84 | BRS3 (0.43) | BRS3MEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL19616868 | 0.79 | MAPT (0.40) | ALDH1A1LMNAKDM4ETP53MAPT | |
| SCHEMBL19948160 | 0.79 | CFTR (0.38) | CFTRALDH1A1LMNASMN1; SMN2CDK1 | |
| SCHEMBL21315097 | 0.76 | C5AR1 (0.48) | CFTRBRS3ALDH1A1KDM4EHPGD | |
| SCHEMBL19948723 | 0.73 | TLR9 (0.43) | JAK1 | |
| SCHEMBL19616667 | 0.73 | TLR9 (0.43) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CFTR 95/4885BRS3 4677/4885ALDH1A1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.